ADVANCED DRUG DELIVERY SYSTEM AND METHOD OF TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMAZEPINE

Abstract: The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 mu g/ml to about 12 mu g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.

Description: ADVANCED DRUG DELIVERY SYSTEM AND METHOD OF TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMAZEPINE The present invention relates to a method of delivery for carbamazepine which will provide steady and consistent blood levels of carbamazepine. The blood levels of carbamazepine are within a therapeutic range required for the treatment of epilepsy as well as other psychiatric, neurological and other disorders. Carbamazepine is an iminostilbene derivative that is used clinically to treat seizure disorders, trigeninal neuralgia, and most recently, manic depressive illness. C.?vbamazepine is also known to those skilled in the art to be i..soluble or difficult to solublize. In addition, it is also difficult to achieve high loading of such a carbamazepine in a pellet form. The term high loading as used in this application shall mean at least sixty percent (60%) by weight of such carbamazepine. As used herein and as known in the art, the term robust pellets shall mean pellets capable of retaining their physical integrity during and after processing into a dosage form and undergoing standard coating procedures. The present invention provides a method and composition for delivery of carbamazepine which provides steady and consistent blood levels of carbamazepine within a therapeutic range. The therapeutic range is from about 6μg/ml to about 12μg/ml of carbamazepine over a period of time. Blood levels of carbamazepine of less than 4μg/ml have been found to be ineffective in treating clinical disorders and blood levels greater than 12μg/ml have been found to be likely to result in undesirable side effects such as neuromuscular disturbances, cardiovascular and gastrointestinal effects. The present invention provides for the maintenance of blood levels of carbamazepine (C) so as to minimize Cmax/Cmin variation or fluctuation. An acceptable fluctuation in the blood level Cmin/Cmax ratio would be a range of from about 0.6 to about 1.0. Most preferably, the variation or fluctuation would range from about 0.8 to about 1.0. The present invention maintains a therapeutic range of blood levels of carbamazepine effective for the treatment of disorders which include but are not limited to depression, trigeminal; neuralgia; chronic pain states; headaches; addictive states for: cocaine, alcohol, opiates and nicotine; other obsessive compulsive disorders and cardiovascular disease. An embodiment of the present invention provides for a sustained release method of delivery of carbamazepine which is to be administered at least once a day, preferably twice a day; therefore, in accordance with an aspect of the present invention there is provided a method for maintaining in a patient, steady and consistent blood level of carbamazepine within therapeutic range of from about 4 μg/ml to about 12 μg/ml, over a time period of at least 12 hours. In accordance with the present invention, within the hereinabove noted therapeutic range, the blood concentration of carbamazepine varies by not more than 60 percent and preferably by not more than 40 percent and most preferably by not more than 20% over a period of at least twelve hours. The method of delivery of carbamazepine of the present invention provides for the following routes of administration sublingual, transmucosal, transdermal, parenteral and preferably oral. Parenteral administration would require an amount of carbamazepine of from about lOOmg to about lOOOmg per 12 hours. The dosage forms may include but are not limited to liquids, tablets, capsules, sprinkle dosage forms, chewable tablets, pellets and transdermal patches. It is anticipated by this application that it may be possible to produce the pellets as described herein other than as robust pellets. One aspect of the present invention provides for a sustained release method of delivery which includes administering one or more single unit dosage forms of equal or varying concentration of carbomazepine. Each such unit is designed to release its contents at varying times over at least a twelve hour time period so as to maintain a carbamazepine blood level within the therapeutic range previuosly described. The term W/W as used herein is representative of a weight to weight ratio of the material specified to the weight of the unit dosage form as a whole. To achieve and maintain the therapeutic range, a dose of from about 400 to about 600 g per 12 hour period of carbamazepine is needed. Due to this, it is preferred to have greater than 30% (W/W) of the pellet content as carbamazepine. The following are representative examples of the various ingredients which may be included in the sustained-release formulation. For carbamazepine, it is preferred to have three different types of units in a single form multiple-unit dosage form. The first unit is an immediate release dosage form, preferably in pellet form. This component can also be a powder if necessary. In either case, the pellet should have a surface-active agent such as sodium lauryl sulf te, sodium monoglycerate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, glyceryl monostearate, glyceryl monooleate, glyceryl monobutyrate, any one of the Pluronic line of surface-active polymers, or any other suitable material with surface active properties or any combination of the above. Preferably the surface-active agent would be a combination of sodium monoglycerate and sodium lauryl sulfate. The concentration of these materials in this component can range from about 0.05 to about 10.0% (W//W) . The pellet should be made via a suitable process which makes the dosage form into a reasonably round unit. This process can be, for example, simple granulation, followed by seiving; extrusion and marumerization; rotogranulation; or any agglomeration process which results in a pellet of reasonable size and robustness. As stated earlier, it is also possible to have this immediate release component as a powder, although the preferred form is a pellet due to mixing and de-mixing considerations. The materials to be admixed along with the drug and surfactant for this first pellet should possess sufficient binding properties to allow agglomeration to occur. These materials can be, but are not limited to, microcrystalline cellulose (such as Avicel), corn starch, pregelatinized starch (such as Starch 1500 or National 1551), potato starch, sodium carboxyme thylated starch, sodium carboxymethylated cellulose, hydroxypropylmethyl cellulose, hydroxypropylcellulose, hydroxyethylcellulose, ethylcellulose, as well as any cellulose ether. In addition, any binder material such as gums (ex. Guar Gum) natural binders and derivatives such as alginates, chitosan, gelatin and gelatin derivatives, are also useful. Synthetic polymers such as polyvinylpyrrolidone (PVP), acrylic acid derivatives (Eudragit, Carbopol, etc.) and polyethylene glycol (PEG) are also useful as binders and matrix formers for the purpose of this invention. It may be useful to have these materials present in the range of from about 1.0 to about 60.0% (W/W) either in total, or individually in combination with one another. Preferably, these materials should be present in the range of from about 30 to about 50 percent (W/W) . It may also be necessary to incorporate a disintegrant into these pellets in order to facilitate dissolution of the active ingredient. For this purpose, any suitable tablet disintegrant can be utilized here, such as cross-linked sodium carboxymethylcellulose (Ac-Di-Sol), cross-linked sodium carboxymethyl starch (Explotab, Primojel), cross-linked PVP (Plasdone XL) or any other material possessing tablet disintegrant properties. For working examples of the first pellet see Examples 1 through 10 below. The second pellet should have a sustained release profile, and needs to be able to address the changing pH of the GI tract, and its effect on the absorption of carbamazepine. This pellet should have all of the ingredients as mentioned for pellet A, as well as some organic acid which will be useful to reduce the pH of the microenvironment of the pellet, and thus facilitate dissolution. These materials are, but not limited to, citric acid, lactic acid, tartaric acid, or other suitable organic acids. These materials should be present in concentrations of from about 0 to about 15.0% (W/W), preferably these materials would be present in concentrations of from about 5.0 to about 10.0 percent (W/W) . The process for manufacturing these pellets is consistent to the process described above for the previous pellet. In addition to the pellet, this component should have a controlling coat applied to the surface of the pellet such that the release of the drug from the pellet is controlled and released over a 6-10 hour period. The materials used for this purpose can be, but are not limited to, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, nitrocellulose, carboxymethylcellulose, and any other cellulose ether, as well as copolymers of ethacrylic acid and methacrylic acid (Eudragit), or any other acrylic acid derivative (Carbopol, etc.) can be used. In addition, an enteric coating material can also be employed, either singularly, or in combination to the above non-pH sensitive coatings. These materials include, but are not limited to, hydroxypropylmethylcellulose phthalate and the phthalate esters of all the cellulose ethers. In addition, phthalate esters of the acrylic acid derivatives (Eudragit), or cellulose acetate phthalate. These coating materials can be employed in coating the surfaces in a range of from about 1.0% (W/W) to about 25% (W/W). Preferably these coating materials should be in a range of from about 8.0 to about 12.0 percent (W/W). For working examples of the second pellet, see Examples 11 through 20 below. The third pellet in this system should be qualitatively similar to the second pellet, in that the manufacturing process for producing this pellet is consistent with that of the first two pellets, and the microenvironment inside the pellet should be consistent with that of pellet B. However, this pellet should have some internal- component breaking down in the pH of the lower GI tract. Thus, it will be necessary to include some enteric or pH sensitive material into the pellet to facilitate erosion and breakdown in the lower GI tract. This material can be, but is not limited to, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, any additional cellulose ether phthalates, any of the acrylic acid derivative phthalates (Eudragit), as well as any enteric coating material, such as shellac, zein, or others. The concentration of these materials in the pellet should be from about 1.0 to about 15.0% (W/W), preferably the concentration of materials should be from about 5.0 to about 10.0 percent (W/W). The coating of this third pellet should be similar to the coating for pellet B, except that it should have a considerable pH sensitivity associated with it. Therefore, it would be desirable to coat pellet C with any of the pH sensitive, or enteric coating materials listed above, either singularly, or in combination with any coating material mentioned above. This coating level of this pellet should range from about 1.0 to about 15.0% (W/W), preferably the concentration of materials should be from about 5.0 to about 12.0 percent (W/W) . For working examples of the third pellet, see Examples 21 through 28 below. Each pellet should have its own dissolution profile associated with the formulation assigned to it. The target dissolution curves for the three units can be seen in Figure 1. This figure shows a schematic of the three units, as well as the target dissolution for the materials. Depending on the formulation chosen in this invention, the exact ratios of each of the pellets may need to be adjusted. The amount of the first unit in the formulation should preferably range from about 5.0 to about 25.0%. The amount of the second unit in the dosage form should range from about 15.0 to about 90.0%. The dosage form for the third unit should be in a range of from about 5.0 to about 30.0%. In accordance with another aspect of the present invention, there is provided a pharmaceutical composition in the form of robust pellets, in which carbamazepine is present in high loading. More particularly, the robust pellets contain the carbamazepine in an amount of at least sixty (60) percent, preferably seventy (70) percent or more, and most preferably eighty (80) percent or more by weight. The pellets are formed with a binder which is ' a pharmaceutically acceptable carrier which is comprised of an amphiphilic polymer having both hydrophobic and hydrophilic properties. The amphiphlic polymer preferably is also capable of forming both water in oil and oil in water emulsions; such a polymer would usually have both a hydrophobic and a hydrophilic portion. In general, such a polymer can be produced from a monomer having both a hydrophobic moiety and a hydrophilic moiety or by copolymerizing a hydrophobic monomer with a hydrophilic monomer. In preparing the robust pellets, the amphiphilic polymer which is used as a binder or carrier in forming the robust pellets, is provided in the formulation prior to robust pellet formation. The formulation which includes the active pharmaceutical, the hereinabove described amphiphilic polymer and any other ingredients to be included in formulating the robust pellets, is then granulated to produce solid robust pellets containing a high loading of carbamazepine. The pharmaceutically acceptable amphiphilic polymer used in the present invention may be comprised of solid amphiphilic polymer or a solution of amphiphilic polymer or a mixture of both depending upon the surface active properties of the amphiphilic polymer being used. Although applicant does not intend to be bound to any theoretical reasoning, carbamazepine tends to be hydrophobic in nature and it is believed that amphiphilic polymers which have more hydrophobic tendencies (higher surface active properties) act as better binders for the high loading of carbamazepine. Therefore depending upon the specific amphiphilic polymer being used, and whether the polymer exhibits higher surface active properties as a solid or as a solution, will determine whether it is be best to use a mixture of a solution of the amphiphilic polymer and solid amphiphilic polymer in the robust pellet forming formulation; or whether it is best to use a solution of the amphiphilic polymer alone in the robust pellet forming formulation. The appropriate amphiphilic polymer formulation can then be granulated into robust pellets while still achieving a high lording of active insoluble pharmaceutical. In some cases, it may also be possible to provide an amphiphilic polymer for use in the formulation by blending a polymer which does not include both a hydrophobic and a hydrophilic portion with a surfactant to thereby provide a polymer with surface activity. When using a mixture of solid amphiphilic polymer and a solution of amphiphilic polymer in producing robust pellets, the present invention provides that the solution of the amphiphilic polymer make up no less than five percent (5%) by weight of the mixture of the solution of the amphiphilic polymer and the solid amphiphilic polymer. Preferably, the solution of the amphiphilic polymer is no more than seventy percent (70%) by weight of the total mixture of the solution of the amphiphilic polymer and the solid amphiphilic polymer. Most preferably, the solution of the amphiphilic polymer makes up from about forty percent (40%) by weight to about sixty (60%) by weight of the total mixture of the solution of the amphiphilic polymer and the solid amphiphilic polymer. In general, the polymer solution contains from 4% to 20%, by weight, of the polymer. In another embodiment of the present invention, there is used a mixture of the amphiphilic polymer wherein the same amphiphilic polymer is to be used for both the solution and solid amphiphilic polymers. Additionally, the present invention also provides for two different amphiphilic polymers to be used for the solution and solid amphiphilic polymers. The amphiphilic polymer used in the present invention may be any of a wide variety of pharmaceutically acceptable amphiphilic polymers. As representative examples thereof, there may be generally mentioned, all vinylpyrrolidone derivates, all polyhydroxls and all ethoxylated polymers that have surface-active properties. As representative of more specific examples there may be mentioned polyvinylpyrrolidone (PVP), PVP-VA copoly ers (Kollidon VAG4), Polyether maleic anhydride, polyethylene glycol, polysorbates esterified celluloses, polyacrylates, polyvinylacetates or pluronics, for example, block copoly ers of oxyethylene and oxypropylene. In general most of pharmaceutically acceptable amphiphilic polymers, described above, should have a number average molecular weight of at least 5000 and preferably at least 50,000. In a preferred embodiment the amphiphilic polymer is polyvinylpyrrolidone, having a high number average molecular weight. High molecular weight polyvinylpyrrolidones are known in the art as having a molecular weight of at least 100,000. As representative of a polyvinylpyrrolidones having a high number average molecular weight there may be mentioned PVP K-90 which has a number average molecular weight of 360,000. In addition to the amphiphilic polymer and carbamazepine, the pellets may include other materials used in the formation of pharmaceutical pellets. Representative examples of such ingredients may include but are not limited to pharmaceutically acceptable fillers, surface active agents, binders and disintegrants, specific examples of which are described below. A preferred embodiment of the present invention provides that such robust pellets contain an amount of carbamazepine capable of maintaining the patient's blood concentration at from about 4μg/ml to about 12μg/ml over at least a 12 hour time period, where the blood concentration of carbamazepine does not vary by more than 20%. Another embodiment of the present invention provides for a composition for treating a patient comprising an effective amount of carbamazepine and a pharmaceutically acceptable carrier which are sufficient for maintaining a blood concentration of carbarns-.repine within the therapeutic range and as described above. Using such dosage form it is preferred that the dose of carbamazepine administered each 24 hour period is from about 800 mg to about 1200 g. The dose is adjusted by the administering physician based upon the age, sex and weight of the patient to maintain therapeutic blood levels of carbamazepine. Since carbamazepine is. needed to be absorbed into the bloodstream over at least a twelve-hour period, it is preferred that the drug be administered in a dosage form that will reliably remain in the GI tract, in a sufficiently high region as to favor absorption. To achieve and maintain the therapeutic range, a dose of from about 400 to about 600 mg per 12 hour period of carbamazepine this makes it necessary to have a high loading of drug in the pellets. Another object of the present invention provides a method for producing robust pellets of carbamazepine which comprises blending a pellet forming formulation which includes a mixture of pharmaceutically acceptable amphiphilic polymer, and an carbamazepine, which is then granulated into robust pellets. In a preferred embodiment of the present invention the pharmaceutical composition contains at least sixty percent (60%), preferably, seventy percent (70%) or more by weight of the carbamazepine. Most preferably, the present invention provides for a pharmaceutical composition which contains eighty percent (80%) or more of the carbamazepine by weight. As representative examples of such carbamazepine there may be mentioned the following: carbamazepine, ibuprofen, gemfibrizole, flutamide, estradiol, alprazolam, triazolam, lorazepam, and indomethacin. The term W/W as used herein is representative of a weight to weight ratio of the material specified to the weight of the unit dosage form as a whole. In accordance with a preferred embodiment of the present invention, there is provided robust pellets in which carbamazepine is present in high loading. In a particularly preferred embodiment there is produced three different types of pellets containing carbamazepine as the carbamazepine, one of which is an immediate release formulation, the second of which is a slow release formulation and the third of which is an pH-dependent formulation. In general, the three different types of pellets are combined into a single dosage form for oral delivery. The immediate release formulation has a high loading of carbamazepine and may or may not be formed as a robust pellet formulation. However, the pellet is formed it must allow for the quick release of the carbamazepine. The slow release and pH-dependent formulation are formulated as robust pellets with a high loading of carbamazepine, most preferably, by using a high number average molecular weight polyvinylpyrrodidone having a number average molecular weight of at least 100,000, as the amphiphilic polymer (the carrier or binder) for forming the robust pellets. In producing the robust pellets the polyvinylpyrrolidone (PVP) is preferably provided in the formulation, prior to pellet formation, as a solution of PVP. Although having 100% of the amphiphilic polymer in solution is preferred, it may be possible to utilize a mixture of both solid polyvinylpyrrolidone (PVP) and a solution of polyvinylpyrrolidone, wherein the solution of PVP is no less than fifty percent (50%) of the mixture, preferably no less than seventy percent (70%) of the mixture of solid PVP and solution of PVP. The PVP solution should contain from about 4% to about 20% by weight of the PVP. In addition to the high loading of carbamazepine, the first unit is formulated with ingredients of a type generally employed in producing an immediate release dosage form. These materials can be, but are not limited to, microcrystalline cellulose (such as Avicel), corn starch, pregelatinized starch (such as Starch 1500 or National 1551), potato starch, sodium carboxymethylated starch, sodium carboxymethylated cellulose, hydroxypropylmethyl cellulose, hydroxypropylcellulose, hydroxyethylcellulose, ethylcellulose, as well as any cellulose ether. It may also be necessary to incorporate a disintegrant into this first unit in order to facilitate dissolution of the carbamazepine. For this purpose, any suitable tablet disintegrant can be utilized here, such as cross-linked sodium carboxymethylcellulose (Ac-Di-Sol), cross-linked sodium carboxymethyl starch (Explotab, Primojel), cross-linked PVP (Plasdone XL) or any other material possessing tablet disintegrant properties. In the second unit, in addition to the carbamazepine and PVP the unit is formulated with ingredients of a type generally employed in producing a sustained release dosage form. These ingredients need to be able to address the changing pH of the GI tract, and its effect on the absorption of carbamazepine. This pellet should have some organic acid which will be useful to reduce the pH of the microenvironment of the pellet, and thus facilitate dissolution. These materials are, but not limited to, citric acid, lactic acid, tartaric acid, or other suitable organic acids. These materials should be present in concentrations of from about 1 to about 15.0% (W/W), preferably these materials would be present in concentrations of from about 5.0 to about 10.0 percent (W/W) . The process for manufacturing these units are consistent with the process described above for the first unit. In addition the second unit should have a controlling coat applied to the surface of the unit such that the release of the pharmaceutical from the unit is controlled and released over a 6-10 hour period. The materials used for this purpose can be, but are not limited to, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, nitrocellulose, carboxymethylcellulose, and any other cellulose ether, as well as copolymers of ethacrylic acid and methacrylic acid (Eudragit), or any other acrylic acid derivative (Carbopol, etc.) can be used. In addition, an enteric coating material can also be employed, either singularly, or in combination to the above non-pH sensitive coatings. These materials include, but are not limited to, hydroxypropylmethylcellulose phthalate and the phthalate esters of all the cellulose ethers. In addition, phthalate esters of the acrylic acid derivatives (Eudragit), or cellulose acetate phthalate. These coating materials can be employed in coating the surfaces in a range of from about 1.0% (W/W) to about 25% (W/W). Preferably these coating materials should be in a range of from about 10.0 to about 20.0 percent (W/W). In addition to the carbamazepine and PVP the third unit is formulated with ingredients of a type generally employed in producing ph dependent release dosage form. These ingredients should be qualitatively similar to the second unit, in that both the manufacturing process, and the microenvironment inside the unit should be consistent with that of the second unit. However, this unit should have some internal component for breaking down in the pH of the lower GI tract. Thus,, it will be necessary to include some enteric or pH sensitive material into the unit to facilitate erosion and breakdown in the lower GI tract. This material can be, but is not limited to, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, any additional cellulose ether phthalates, any of the acrylic acid derivative phthalates (Eudragit), as well as any enteric coating material, such as shellac, zein, or others. The concentration of these materials in the unit should be from about 0 to about 15.0% (W/W), preferably the concentration of materials should be from about 0 to about 5 percent (W/W). The coating of this third unit should be similar to the coating for the second unit, except that it should have a considerable pH sensitivity associated with it. Therefore, it would be desirable to coat the third unit with any of the pH sensitive, or enteric coating materials listed above, either singularly, or in combination with any coating material mentioned above. The coating level of this unit should range from about 1.0 to about 25.0% (W/W), preferably the concentration of materials should be from about 10.0 to about 20.0 percent (W/W). For working examples of robust core pellet formulations, see Examples 29 through 34 below. Each pellet should have its own dissolution profile associated with the formulation assigned to it. The target dissolution curves for the three units can be seen in Figure 1. This figure shows a schematic of the three units, as well as the target dissolution for the materials. Depending on the formulation chosen in this invention, the exact ratios of each of the pellets may need to be adjusted. The amount of the first unit in the formulation should preferably range from about 5.0 to about 25.0%. The amount of the second unit in the dosage form should range from about 15.0 to about 70.0%. The dosage form for the third unit should be in a range of from about 5.0 to about 30.0%. The formulation described above may for example be used in the treatment of epilepsy as well as other psychiatric, neurological and other disorders. With respect to such treatment, the amount of carbamazepine administered within the 3-unit formulation should be from about 800 mg to about 1200 mg over a 24 hour period. Preferably, carbamazepine is administered within the formulation is in an amount equal to from about 400 mg to 600 mg over a 24 hour period. The therapeutic blood dosage level of the patient being treated should not be less than 4μg/ml and should not exceed 12μg/ml of carbamazepine over at least a 12 hour time period. The dose would be adjusted by the administering physician based upon the age, sex and weight of the patient to maintain therapeutic blood dosage levels. The following examples 1 through 28 are intended to further illustrate not to limit the present invention. The examples are representative of formulations for carbamazepine which do not require robust pellts but which are provided three groups, one for each pellet type as described above. p ellet As Immediate Selease Com onen Microcrystalline Cellulose, N.F.(MCC) (λvicel PH-101/102, Emcocel, etc.) Hydroxypropylmethylcellulose(HPMC) (Methocel E5/E50/K5/K50) Croscaraellose, Type A, N.F. (Ac-Di-Sol) Sodium Lauryl Sulfate (SLS) Carbamazepine Total Example 2t MCC HPMC Sodium Starch Glycolate, N.F. (Explotab, Primojβl) SLS Carbamazepine Total Example 3s MCC Pre-gelatinized Starch (STARCH 1500, National 1551) Croscarmelloβe Corn Starch, U.S.P. (as paste) Dioctyl Sodium Sulfosuccinate (DDS) Carbamazepine Total Example 4s 0.15 0.15 0.05 0.005 Q .S45 1.000 0.2 0.03 0.05 0.08 0.005 0.S35 o a . 1.000 Pellet Aι Immediate Kelease Component Example βs MCC MCC/CMC Croscarmellose DDS Carbamazepine Total . 1.000 Example 7s MCC/CMC 25.0 0.25 Polyacrylic Acid 10.0 0.1 (Carbomer) SLS 0.2 0.002 Sodium Starch Glycolate 7.5 0.075 Carbamazepine 57,3 9.573 Total loo.o 1.000 Example 8s MCC 30.0 0.30 HPMC 7.5 0.075 Croscarmellose 5.0 0.05 Sodium bis-(2-ethylhexyl)sulfo¬ succinate (Aerosol OT) 1.5 0.015 Carbamazepine 56.0 Ptggg Total 100.0 1.000 Example fi MCC 25.0 0.25 HPMC 5.0 0.05 Mono/Di/Tri-glyceride Mixture (λtmul-84S) 10.0 0.1 SLS 0.5 0.005 Carbamazepine 5?.5 Total 100.0 1.000 Example 10s MCC 25.0 0.25 Polyviny1 yrrolidone (PVP) (Plasdone) 8.0 0.08 Sodium Monoglycerate (Myvaplex) 8.0 0.08 SLS 0.35 0.0035 Carbamazepine 5g.« Total loo.oo 1.0000 -r«^A« s* βMMiβau «•-_.««•• ssapoαtac Example 11s MCC HPMC Sodium Monoglycerate Tartaric Acid SLS Carbamazepine Total Coating: Example 12s Same core pellet as in example 11 Coating: HPMC (Methocel E50) 45.0 0.45 Ethylcellulose (Ethocel) 45.0 0.45 PolyethyleneGlycol 400 (PEG400) 10-0 0.10 Total 100.0 1.00 Example 13s Same core pellet as in example 11 Coating: HPMC 20.0 0.20 Ethylcellulose 70.0 0.70 FEG400 10.0 0.10 Total 100.0 1.00 Example 1 MCC 15.0 0.15 MCC/CMC Mixture 15.0 0.15 Citric Acid 8.0 0.06 DSS 0.8 0.008 Carbamazepine «.2 Total 100.0 1.000 Example 14 (oont±aued) Coating: HPMC (Methocel K5M) 10.0 0.10 HPMC (Methocel E50) 14.0 0.14 Ethylcellulose 66.0 0.66 PEG400 10.0 0.10 Total 100.0 1.00 Example 15s Core pellet from example 14 Coating from example 11 Example let Core pellet from example 14 Coating from example 12 Example lit Core pellet from example 14 Coating from example 13 Example 17s MCC PVP Mono/Di/Tri-Glyceride Mixture SLS Tartaric Acid Carbamazepine Total Coating: Coating from example 11 Example Its Core pellet from example 17 Coating from example 12 Core pellet from example 17 Coating from example 13 20 : Core pellet from example 17 Coating from example 14 Pellet Cs Delayed Release Component Example 21s Core Pellet: MCC Hydroxypropylmethylcellulose Phthalate (HPMCP) Tartaric Acid Sodium Monoglycerate DSS Carbamazepine Total Coating: Cellulose Acetate Phthalate (CAP) Ethylcellulose PEG400 Total Example 22s Cnr» pellet from example 21 Coating: Example 23s Core pellet from example 21 Coating: CAP HPMCP PEG 400 PEG 8000 Total Core Pellet: MCC Mono/Di/Tri-glyceride Mixture Tartaric Acid CAP DSS Carbamazepine Total Coating as in example 21 Example 25s Core pellet as in example 24 Coating as in example 22 Example 26s Core Pellet as in example 24 Coating as in example 23 Example 27t Core pellet as in example 24 Coating: Shellac 85.0 0.85 Mineral Oil 13.0 0.13 SLS 0.5 0.005 Talc 1.5 9,015 Total 100.0 1.000 Example 28s Core pellet as in example 21 Coating as in example 27 The following Examples 29-34 represent robust core pellet formulations. The pellet should be made via a suitable process which makes the dosage form into a reasonably round unit. This process can be, for example, simple granulation, followed by seiving; extrusion and marumerization; rotogranulation; or any agglomeration process wich results in a pellet of reasonable size and robustness. To produce enteric or ph dependent or sustained release robust pellets one would need to coat these robust core pellets with the appropriate coating. In addition, it is to be understood, that the scope of the present invention is not to be limited to the specific embodiments described herein and that the invention may be practiced other than as particularly described and still be within the scope of the accompanying claims. EXAMPLE ONE %W/W INGREDIENT AMOUNT 80.00 Carbamazepine, USP 32.00 kg 2.5 Microcrystalline Cellulose, NF (Avicel PH-101) 1.00 kg 5.0 Lactose, NF (Hydrous, 310) 2.00 kg 5.0 Tataric Acid, USP (Anhydrous) 2.00 kg 0.5 Sodium Lauryl Sulfate, NF 0.20 kg 5.0 PVP-VA Copolymer (Kolidon VAG4) 2.00 kg 1.5 Talc, USP 0.60 kg 0.5 Polyethylene Glycol 400, NF 0.20 kg * Purified Water, USP 12.00 kg 100.00 40.00 kg ♦Purified Water, USP is removed during processing. EXAMPLE TWO %W/W INGREDIENT AMOUNT 80.00 Carbamazepine, USP 32.00 kg 2.5 Microcrystalline Cellulose, NF 1.00 g (Avicel PH-101) 5.0 Lactose, NF (Hydrous, 310) 2.00 kg 5.0 Citric Acid, USP (Anhydrous) 2.00 kg 0.5 Sodium Lauryl Sulfate, NF 0.20 kg 5.0 Povidone, USP (K-90) 2.00 kg 1.5 Talc, USP 0.60 kg 0.5 Polyethylene Glycol 400, NF 0.20 kg * Purified Water, USP 12.00 kg 100.00 40.00 kg ♦Purified Water, USP is removed during processing. EXAMPLE THREE %W/W INGREDIENT AMOUNT 80.00 Carbamazepine, USP 32.00 kg 5.0 Microcrystalline Cellulose, NF 2.00 kg (Avicel PH-101) 2.5 Lactose, NF (Hydrous, 310) 1.00 kg 5.0 Ascorbic Acid, USP (Anhydrous) 2.00 kg 0.5 Sodium Lauryl Sulfate, NF 0.20 kg 4.0 Polyethylene Glycol 8000 1.60 kg 1.0 Polyethylene Glycol 400 0.40 kg 1.5 Talc, USP 0.60 kg ♦ Purified Water, USP 12.00 kg 100.00 40.00 kg ♦Purified Water, USP is removed during processing. EXAMPLE FOUR %W/W INGREDIENT AMOUNT 80.00 Carbamazepine , USP (Screened) 32.00 kg 2.5 Microcrystalline Cellulose, NF 1.00 kg (Avicel PH-101) 5.0 Lactose, NF (Hydrous, 310) 2.00 kg 5.0 Tartaric Acid, USP (Anhydrous) 2.00 kg 0.5 Sodium Lauryl Sulfate, NF 0.20 kg 5.0 Polyether Maleic Anhydride 2.00 kg 0.5 Magnesium Stearate, USP 0.20 kg 1.0 Talc, USP 0.40 kg 0.5 Poloxamer 338 0.220 kg ♦ Purified Water, USP 12.00 kg 100.00 40.00 kg ♦Purified Water, USP is removed during processing. EXAMPLE FIVE %W W INGREDIENT AMOUNT 80.00 Carbamazepine, USP 32.00 kg 2.5 Microcrystalline Cellulose, NF 1.00 kg (Avicel PH-101) 5.0 Lactose, NF (Hydrous, 310) 2.00 kg 5.0 Ascorbic Acid, USP 2.00 kg 0.1 Sodium Lauryl Sulfate, NF 0.04 kg 2.5 Polyoxamer 237, NF 1.00 kg 2.5 Polyoxamer 188, NF 1.00 kg 1.5 Talc, USP 0.60 kg 0.5 Polyethylene Glycol 400, NF 0.20 kg ♦ Purified Water, USP 12.00 kg 100.00 40.00 kg ♦Purified Water, USP is removed during processing. EXAMPLE SIX W/W INGREDIENT AMOUNT 80.00 Carbamazepine, USP 32.00 kg 2.5 Microcrystalline Cellulose, NF 1.00 kg (Avicel PH-101) 5.0 Lactose, NF (Hydrous, 310) 2.00 kg 5.0 Citric Acid, USP 2.00 kg 0.5 Sodium Lauryl Sulfate, NF 0.20 kg 5.0 Polyethylene Oxide, NF 2.00 kg 1.5 Talc, USP 0.60 kg 0.5 Glycerin, USP 0.20 kg ♦ Purified Water, USP 12.00 kg 100.00 40.00 kg ♦Purified Water, USP is removed during processing.

Claims: WHAT IS CLAIMED IS: 1. A method of treating a patient comprising: administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4μg/ml to about 12μg/ml over at least a 12 hour time period, 2. A method of treating a patient as in Claim 1, wherein said blood concentration of carbamazepine does not vary by more than 60 percent. 3. A method of treating a patient as in Claim 2, wherein said blood concentration of carbamazepine does not vary by more than 40 percent. 4. A method of treating a patient as in Claim 2, wherein the carbamazepine is administered in an amount equal to from about 400 to about 600 mg per 12 hours of carbamazepine. 5. A method of treating a patient as in Claim 2, wherein the blood concentration of carbamazepine does not vary by more than 20 percent. 6. A method of a treating a patient as in Claim 2, wherein the carbamazepine is administered twice daily. 7. A composition for the oral administration of carbamazepine comprising: (i) an effective amount of carbamazepine; and (ii) a pharmaceutically acceptable carrier, capable of maintaining a patient's blood concentration of carbamazepine of from about 4μg/ml to about 12μg/ml over at least a 12 hour time period. 8. A composition as in Claim 7, wherein said composition comprises: a single form which contains multiple units, which collectively contain an effective amount of carbamazepine said multiple units being capable of releasing their contents at varying times. 9. A composition as in Claim 8, wherein said multiple units consist of three pellets, an immediate release pellet, a sustained-release pellet and a sustained-release enteric-sensitive pellet. 10. A solid composition for the oral administration of carbamazepine, comprising: (a) a sustained release unit containing carbamazepine; (b) an immediate release unit containing carbamazepine; and (c) an enteric release unit containing carbamazepine, said combination of components (a), (b), and (c) containing an effective amount of carbamazepine. 11. A composition as in Claim 10, wherein each of the units includes a surfactant. 12. A composition as in Claim 11, wherein the sustained release unit and the enteric release unit each contain an organic acid to maintain an acidic environment in the units. 13. A composition as in Claim 12, wherein the composition contains a plurality of each of the units and the combination of units includes carbamazepine in an amount effective to maintain a blood dosage level of carbamazepine within the range of from about 4 μg/ml to about 12 μg/ml over at least a 12 hour time period. 14. A composition as in Claim 13, wherein said composition has an amount of carbamazepine from about 400 mg to about 600 mg per 12 hour time period. 15. A composition as in Claim 13, wherein the blood dosage level of carbamazepine within said range does not vary by more than 60 percent per 12 hour period. 16. A composition as in Claim 15, wherein the blood dosage level of carbamazepine within said range does not vary by more than 20 percent per 12 hour period. 17. A composition as in Claim 13, wherein said surfactant is sodium lauryl sulfate. 18. A method of treating a patient with carbamazepine comprising: orally administering to said patient a composition which contains, (a) multiple immediate release units containing carbamazepine; (b) multiple sustained release units containing carbamazepine; (c) multiple enteric release units containing carbamazepine; said components (a), (b), and (c) containing an effective amount of carbamazepine. 19. A method as in Claim 18, wherein said components (a), (b), (c) being administered in a combined amount to maintain a blood dosage level of carbamazepine within a range of from about 4 μg/ml to about 12 μg/ml for a period of at least 12 hours. 20. A method as in Claim 18, wherein the components being administered contain a combined amount of carbamazepine of from about 400 mg to about 600 mg per 12 hour period. 21. A method as in Claim 19, wherein the blood dosage level of carbamazepine does not vary by more than 60 percent per 12 hour period. 22. A method as in Claim 20, wherein the blood dosage level of carbamazepine within said range does not vary by more than 20 percent per 12 hour period. 23. A method as in Claim 18, wherein each of the units includes a surfactant. 24. A method as in Claim 22, wherein said surfactant is sodium lauryl sulfate. 25. A method as in Claim 23, wherein said sustained release unit and said enteric release unit each contain an organic acid to maintain an acidic environment in the units. 26. A pharmaceutical composition comprising: said composition being a robust pellet, having an carbamazepine having a loading of at least sixty percent and having a binder containing amphiphilic polymer in an amount sufficient to form said robust pellet. 27. A pharmaceutical composition as in Claim 26, wherein said amphiphilic polymer has a number average molecular weight of at least 5,000. 28. A pharmaceutical composition as in Claim 27, wherein said amphiphilic polymer has a number average molecular weight of at least 50,000. 29. A pharmaceutical composition as in Claim 28, wherein said amphiphilic polymer is high number average molecular weight polyvinylpyrrolidone. 30. A pharmaceutical composition as in Claim 29, herein said polyvinylpyrrolidone has a number average molecular weight of at least 100,000. 31. A pharmaceutical composition as in Claim 30, wherein said active pharmaceutical is carbamazepine. 32. A method for producing robust pellets of carbamazepine, said method comprising: producing said robust pellets from a pellet forming formulation of an amphiphilic polymer, and an carbamazepine. 33. A method as in Claim 32, wherein said active pharmaceutical is carbamazepine. 34. A method as in Claim 33, wherein said amphiphilic polymer is a high number average molecular weight polyvinylpyrrolidone, having a number average molecular weight of at least 100,000.

Inventors: BELENDIUK GEORGE W, RUDNIC EDWARD M, BELENDIUK, GEORGE, W., RUDNIC, EDWARD, M.
Applicants: PHARMAVENE INC, PHARMAVENE, INC.
Application year: 1992
Main classification: A61K9
IPC codes: A61K9, A61K31